Episode 323 - Carlos Villagran Discusses Rebuilding a Corporate Culture After a Crisis
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 186: White Collar Crimes in Healthcare with Maynard Nexsen’s White Collar Team
AGG Talks: Antitrust and White-Collar Crime Roundup - Analyzing the Latest Updates in the Litigation Against Trump
What are three things that the Commission for the Control of INTERPOL’s Files won’t do, and why?
The Sentencing Guidelines at Thirty
Bar Exam Toolbox Podcast Episode 175: Listen and Learn -- Inchoate Offenses (Criminal Law)
RICO Conduct (18 U.S.C. §§ 1962(a-d)) - RICO Report Podcast
The Justice Insiders: FIFA Corruption Trial – Will the Feds Score Another Goal?
Digging Deeper, Episode 1: The Con Queen of Hollywood
Compliance Perspectives: The Right Kind of Wrong
Episode 119 -- The Ericsson FCPA Settlement
Episode 117 -- FCPA Update: Samsung FCPA Settlement; Braskem Former CEO Indicted; Transport CEO Convicted after Trial
Episode 116 -- Alstom Executive Convicted of FCPA and Money Laundering Offenses
Podcast: Non-binding Guidance: Examining FDA’s Enforcement Authority Over Stem Cell Clinics and Compounders
Jones Day Presents: Antitrust, Collusion, and Blockchains
Report on Research Compliance 19 no. 6 (June, 2022) - Auditors for the National Science Foundation (NSF) Office of Inspector General (OIG) questioned $35,316 of costs claimed by the University of Idaho (UI) among $42.7...more
Report on Research Compliance 18, no. 6 (June 2021) - Clemson University is pushing back against recommendations by auditors for the National Science Foundation Office of Inspector General (OIG) that it repay $276,440,...more
Report on Research Compliance 18, no. 2 (February 2021) - A National Science Foundation (NSF) Office of Inspector General (OIG) audit of five Established Program to Stimulate Competitive Research (EPSCoR) awards to the...more
Report on Research Compliance 17, no. 12 (December 2020) - Finalizing a document issued last year, on Nov. 9 the Food and Drug Administration issued “Enhancing the Diversity of Clinical Trial Populations—Eligibility...more